TSX:TRIL

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. More Details


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has Trillium Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TRIL is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: TRIL's weekly volatility has decreased from 17% to 11% over the past year.


Market Performance


7 Day Return

-12.9%

TRIL

2.9%

CA Biotechs

0.7%

CA Market


1 Year Return

197.7%

TRIL

18.0%

CA Biotechs

2.1%

CA Market

Return vs Industry: TRIL exceeded the Canadian Biotechs industry which returned 26.6% over the past year.

Return vs Market: TRIL exceeded the Canadian Market which returned 2% over the past year.


Shareholder returns

TRILIndustryMarket
7 Day-12.9%2.9%0.7%
30 Day6.7%24.0%4.6%
90 Day-2.6%15.5%13.5%
1 Year197.7%197.7%18.0%18.0%5.8%2.1%
3 Year56.1%56.1%12.7%12.7%13.9%3.1%
5 Year41.5%41.5%25.7%25.7%67.3%41.6%

Long-Term Price Volatility Vs. Market

How volatile is Trillium Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Trillium Therapeutics undervalued compared to its fair value and its price relative to the market?

7.99x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate TRIL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate TRIL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: TRIL is unprofitable, so we can't compare its PE Ratio to the XN Biotechs industry average.

PE vs Market: TRIL is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TRIL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TRIL is overvalued based on its PB Ratio (8.3x) compared to the CA Biotechs industry average (6.9x).


Next Steps

Future Growth

How is Trillium Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

39.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TRIL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TRIL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TRIL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TRIL's revenue (82.4% per year) is forecast to grow faster than the Canadian market (7.9% per year).

High Growth Revenue: TRIL's revenue (82.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if TRIL's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Trillium Therapeutics performed over the past 5 years?

-47.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TRIL is currently unprofitable.

Growing Profit Margin: TRIL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TRIL is unprofitable, and losses have increased over the past 5 years at a rate of 47.7% per year.

Accelerating Growth: Unable to compare TRIL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TRIL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).


Return on Equity

High ROE: TRIL has a negative Return on Equity (-104.3%), as it is currently unprofitable.


Next Steps

Financial Health

How is Trillium Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: TRIL's short term assets ($296.3M) exceed its short term liabilities ($13.2M).

Long Term Liabilities: TRIL's short term assets ($296.3M) exceed its long term liabilities ($100.3M).


Debt to Equity History and Analysis

Debt Level: TRIL is debt free.

Reducing Debt: TRIL has no debt compared to 5 years ago when its debt to equity ratio was 0.3%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TRIL has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: TRIL has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 17.1% each year


Next Steps

Dividend

What is Trillium Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TRIL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TRIL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TRIL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TRIL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TRIL's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure


CEO

Jan Skvarka

1.33yrs

Tenure

US$847,315

Compensation

Dr. Jan Skvarka, Ph.D., Has been the President, Chief Executive Officer and Director of Trillium Therapeutics Inc. since September 25, 2019. Prior to joining Trillium, Dr. Skvarka served as the Chief Execu...


CEO Compensation Analysis

Compensation vs Market: Jan's total compensation ($USD847.32K) is below average for companies of similar size in the Canadian market ($USD2.10M).

Compensation vs Earnings: Insufficient data to compare Jan's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Jan Skvarka
President1.33yrsUS$847.32kno data
James Parsons
Chief Financial Officer9.42yrsUS$441.22kno data
Robert Uger
Chief Scientific Officer7.75yrsUS$533.86kno data
Penka Petrova
Chief Development Officer5.67yrsUS$441.22kno data
Rosemary Harrison
Senior Vice President of Corporate Development & Strategy1yrno data0.000070%
$ 1.2k
Michael Hill
Head of Calgary Siteno datano datano data
Kathleen Large
Senior Vice President - Clinical Operations2yrsno datano data
Ingmar Bruns
Chief Medical Officer0.17yrno datano data

2.0yrs

Average Tenure

Experienced Management: TRIL's management team is considered experienced (2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jan Skvarka
President1.33yrsUS$847.32kno data
Robert Kirkman
Chairman1.75yrsUS$412.33kno data
Paul Walker
Independent Director0.92yrno datano data
Luke Beshar
Independent Director6.83yrsUS$161.44kno data
Steven Rosen
Member of the Scientific Advisory Board0.17yrno datano data
Paolo Pucci
Director0.17yrno datano data
Thomas Reynolds
Member of the Scientific Advisory Board & Independent Director6.83yrsUS$151.93kno data
Michael Kamarck
Director0.33yrno datano data
Helen Tayton-Martin
Independent Director3.25yrsUS$148.89kno data
Karen Jean Ferrante
Member of the Scientific Advisory Board0.17yrno datano data
Jeff Settleman
Member of the Scientific Advisory Board0.17yrno datano data
Gordon Freeman
Member of the Scientific Advisory Board0.17yrno datano data

0.6yrs

Average Tenure

61yo

Average Age

Experienced Board: TRIL's board of directors are not considered experienced ( 0.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 259.2%.


Top Shareholders

Company Information

Trillium Therapeutics Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Trillium Therapeutics Inc.
  • Ticker: TRIL
  • Exchange: TSX
  • Founded: 2004
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$1.731b
  • Shares outstanding: 100.71m
  • Website: https://trilliumtherapeutics.com

Number of Employees


Location

  • Trillium Therapeutics Inc.
  • 2488 Dunwin Drive
  • Mississauga
  • Ontario
  • L5L 1J9
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TRILTSX (The Toronto Stock Exchange)YesCommon SharesCACADJan 2005
R5WPDB (Deutsche Boerse AG)YesCommon SharesDEEURJan 2005
TRILNasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDJan 2005
0VLSLSE (London Stock Exchange)YesCommon SharesGBCADJan 2005

Biography

Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble dec...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/21 23:44
End of Day Share Price2021/01/21 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.